Coenzyme Q 10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes

Diabetologia

Volumn 55, Issue 5, 2012, Pages 1544-1553

  Huynh, K ^a,b   Kiriazis, H ^a   Du, X J ^a,b   Love, J E ^a   Jandeleit Dahm, K A ^a   Forbes, J M ^a   McMullen, J R ^b   Ritchie, R H ^a,b  

^a BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

Antioxidant; Cardiomyopathy; Diabetes; Remodelling; Superoxide

Indexed keywords

PROTEIN KINASE B; RAMIPRIL; SUPEROXIDE; UBIDECARENONE; ANTIHYPERTENSIVE AGENT; DRUG DERIVATIVE; UBIQUINONE; VITAMIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOMYOCYTE HYPERTROPHY; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIASTOLIC DYSFUNCTION; ENZYME PHOSPHORYLATION; FEMALE; HEART MUSCLE FIBROSIS; HYPERGLYCEMIA; HYPERTROPHY; LIPID PEROXIDATION; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; ANIMAL; C57BL MOUSE; CARDIOMEGALY; COMPARATIVE STUDY; DISEASE MODEL; DRUG ANTAGONISM; DRUG EFFECT; ECHOGRAPHY; HEART VENTRICLE REMODELING; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIHYPERTENSIVE AGENTS; APOPTOSIS; CARDIOMEGALY; DIABETES MELLITUS, TYPE 2; DIABETIC CARDIOMYOPATHIES; DISEASE MODELS, ANIMAL; ENDOMYOCARDIAL FIBROSIS; FEMALE; HYPERGLYCEMIA; LIPID PEROXIDATION; MICE; MICE, INBRED C57BL; OXIDATIVE STRESS; PROTO-ONCOGENE PROTEINS C-AKT; RAMIPRIL; SUPEROXIDES; UBIQUINONE; VENTRICULAR REMODELING; VITAMINS;

EID: 84862543941     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-012-2495-3     Document Type: Article

References (50)

1. Shaw JE, Sicree RA, Zimmet PZ (2010) Global estimates of the prevalence of diabetes for 2010 and 2030. Diabetes Res Clin Pract 87 (1): 4-14
2. Fang ZY, Prins JB, Marwick TH (2004) Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev 25: 543-567
3. Rubler S, Yuceoglu YZ, Kumral T, Grishman A, Branwood AW, Dlugash J (1972) New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 30: 595-602
4. Schannwell CM, Schneppenheim M, Perings S, Plehn G, Strauer BE (2002) Left ventricular diastolic dysfunction as an early manifestation of diabetic cardiomyopathy. Cardiology 98: 33-39
5. Asbun J, Villarreal FJ (2006) The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 47: 693-700
6. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2002) Oxidative stress and stress-activated signaling pathways: a unifying hypothesis of type 2 diabetes. Endocr Rev 23: 599-622
7. Haidara MA, Yaseen HZ, Rateb M, Ammar H, Zorkani MA (2006) Role of oxidative stress in development of cardiovascular complications in diabetes mellitus. Curr Vasc Pharmacol 4: 215-227
8. Maritim AC, Sanders RA, Watkins JB (2003) Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 17: 24-38
9. Fiordaliso F, Bianchi R, Staszewsky L et al (2004) Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol 37: 959-968
10. Ritchie RH, Quinn JM, Cao AH et al (2007) The antioxidant tempol inhibits cardiac hypertrophy in the insulin-resistant GLUT4-deficient mouse in vivo. J Mol Cell Cardiol 42: 1119-1128
11. Cai L (2006) Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic Biol Med 41: 851-861
12. 10 treatment on antioxidant pathways in normal and streptozotocininduced diabetic rats. J Biochem Mol Toxicol 15: 41-46
13. Coldiron AD, Sanders RA,Watkins JB (2002) Effects of combined quercetin and coenzyme Q (10) treatment on oxidative stress in normal and diabetic rats. J Biochem Mol Toxicol 16: 197-202
14. Langsjoen PH, Langsjoen A,Willis R, Folkers K (1997) Treatment of hypertrophic cardiomyopathy with coenzyme Q (10). Mol Asp Med 18: S145-S151
15. Silver MA, Langsjoen PH, Szabo S, Patil H, Zelinger A (2004) Effect of atorvastatin on left ventricular, diastolic function and ability of coenzyme Q (10) to reverse that dysfunction. Am J Cardiol 94: 1306-1310
16. Sander S, Coleman CI, Patel AA, Kluger J, White CM (2006) The impact of coenzyme Q10 on systolic function in patients with chronic heart failure. J Card Fail 12: 464-472
17. Sourris KC, Harcourt BE, Tang PH et al (2012) Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med 52: 716-723
18. Dunn SR, Qi ZH, Bottinger EP, Breyer MD, Sharma K (2004) Utility of endogenous creatinine clearance as a measure of renal function in mice. Kidney Int 65: 1959-1967
19. Huynh K, McMullen JR, Julius T et al (2010) Cardiac-specific insulin-like growth factor 1 receptor transgenic expression protects against cardiac fibrosis and diastolic dysfunction in a mouse model of diabetic cardiomyopathy. Diabetes 59: 1512-1520
20. Chen ZY, Chua CC, Ho YS, Hamdy RC, Chua BHL (2001) Overexpression of Bcl-2 attenuates apoptosis and protects against myocardial I/R injury in transgenic mice. Am J Physiol-Heart Circul Physiol 280: H2313-H2320
21. Rosenkranz AC, Hood SG, Woods RL, Dusting GJ, Ritchie RH (2003) B-type natriuretic peptide prevents acute hypertrophic responses in the diabetic rat heart-importance of cyclic GMP. Diabetes 52: 2389-2395
22. Laskowski A, Woodman OL, Cao AH et al (2006) Antioxidant actions contribute to the antihypertrophic effects of atrial natriuretic peptide in neonatal rat cardiomyocytes. Cardiovasc Res 72: 112-123
23. McMullen JR, Shioi T, Zhang L et al (2003) Phosphoinositide 3- kinase (p110 alpha) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy. Proc Natl Acad Sci USA 100: 12355-12360
24. Devereux RB, Roman MJ, Paranicas M et al (2000) Impact of diabetes on cardiac structure and function. The strong heart study. Circulation 101: 2271-2276
25. Gonzalez-Vilchez F, Ayuela J, Ares M, Pi J, Castillo L, Martin-Duran R (2005) Oxidative stress and fibrosis in incipient myocardial dysfunction in type 2 diabetic patients. Int J Cardiol 101: 53-58
26. Bonnefont-Rousselot D, Bastard JP, Jaudon MC, Delattre J (2000) Consequences of the diabetic status on the oxidant/antioxidant balance. Diabetes Metab 26: 163-176
27. Chew GT, Watts GF, Davis TME et al (2008) Hemodynamic effects of fenofibrate and coenzyme Q (10) in type 2 diabetic subjects with left ventricular diastolic dysfunction. Diabetes Care 31: 1502-1509
28. Diamant M, Lamb HJ, Groeneveld Y et al (2003) Diastolic dysfunction is associated with altered myocardial metabolism in asymptomatic normotensive patients with well-controlled type 2 diabetes mellitus. J Am Coll Cardiol 42: 328-335
29. Shimizu M, Umeda K, Sugihara N et al (1993) Collagen remodeling in myocardia of patients with diabetes. J Clin Path 46: 32-36
30. Kumar A, Kaur H, Devi P, Mohan V (2009) Role of coenzyme Q10 (CoQ10) in cardiac disease, hypertension and Meniere-like syndrome. Pharmacol Ther 124: 259-268
31. Belke DD, Swanson EA, Dillmann WH (2004) Decreased sarcoplasmic reticulum activity and contractility in diabetic db/db mouse heart. Diabetes 53: 3201-3208
32. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP (1990) Prognostic implications of echocardiographically determined leftventricular mass in the Framingham Heart Study. New Engl J Med 322: 1561-1566
33. Langsjoen PH, Langsjoen A,Willis R, Folkers K (1996) Treatment of hypertrophic cardiomyopathy with coenzyme Q (10). Pergamon, Ancona, Italy, pp S145-S151
34. Frustaci A, Kajstura J, Chimenti C et al (2000) Myocardial cell death in human diabetes. Circ Res 87: 1123-1132
35. Fiordaliso F, Li BS, Latini R et al (2000) Myocyte death in streptozotocin-induced diabetes in rats is angiotensin IIdependent. Lab Invest 80: 513-527
36. Lim SC, Tan HH, Goh SK et al (2006) Oxidative burden in prediabetic and diabetic individuals: evidence from plasma coenzyme Q (10). Diabet Med 23: 1344-1349
37. Bentinger M, Brismar K, Dallner G (2007) The antioxidant role of coenzyme Q. Mitochondrion 7: S41-S50
38. Hodgson JM, Watts GF, Playford DA, Burke V, Croft KD (2002) Coenzyme Q (10) improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes. Eur J Clin Nutr 56: 1137-1142
39. Liang W, Tan CYR, Ang L et al (2008) Ramipril improves oxidative stress-related vascular endothelial dysfunction in db/db mice. J Physiol Sci 58: 405-411
40. Otto A, Fontaine J, Berkenboom G (2006) Ramipril treatment protects against nitrate-induced oxidative stress in eNOS (?/?) mice: an implication of the NADPH oxidase pathway. J Cardiovasc Pharmacol 48: 842-849
41. Aragno M, Mastrocola R, Alloatti G et al (2008) Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology 149: 380-388
42. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM (2002) Pivotal role of a gp91 (phox)-containing NADPH oxidase in angiotensin II-induced cardiac hypertrophy in mice. Circulation 105: 293-296
43. Nakagami H, Takemoto M, Liao JK (2003) NADPH oxidasederived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. J Mol Cell Cardiol 35: 851-859
44. McMullen JR, Shioi T, Huang WY et al (2004) The insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-kinase (p110 alpha) pathway. J Biol Chem 279: 4782-4793
45. Stas SN, El-Atat FA, Sowers JR (2004) Pathogenesis of hypertension in diabetes. Rev Endocr Metab Disord 5: 221-225
46. Su W, Guo ZH, Randall DC, Cassis L, Brown DR, Gong MC (2008) Hypertension and disrupted blood pressure circadian rhythm in type 2 diabetic db/db mice. Am J Physiol-Heart Circ Physiol 295: H1634-H1641
47. Singh RB, Niaz MA, Rastogi SS, Shukla PK, Thakur AS (1999) Effect of hydrosoluble coenzyme Q10 on blood pressures and insulin resistance in hypertensive patients with coronary artery disease. J Hum Hypertens 13: 203-208
48. Rosenfeldt FL, Haas SJ, Krum H et al (2007) Coenzyme Q (10) in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens 21: 297-306
49. Luders S, Schrader J, Berger J et al (2008) The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure-a prospective, randomised, controlled prevention trial of the German Hypertension League. J Hypertens 26: 1487-1496
50. Bugger H, Abel ED (2009) Rodent models of diabetic cardiomyopathy. Dis Model Mech 2: 454-466